PeptideDB

Sodium gualenate

CAS No.: 6223-35-4

Sodium gualenate (Guaiazulenesulfonate sodium) (Guaiazulenesulfonate sodium), a hydrophilic derivative of guaiazulene (G
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Sodium gualenate (Guaiazulenesulfonate sodium) (Guaiazulenesulfonate sodium), a hydrophilic derivative of guaiazulene (GA), is an unstable compound. It has anti-inflammatory and wound-healing effects.
In vivo Sodium gualenate 经常用于治疗人类胃炎。其主要作用机制被定义为细胞保护,即保护胃黏膜[1]。
Animal experiments The anti-gastric ulcer activity of compounds was tested through an ethanol-induced gastric ulcer mouse model method.?Kunming mice, consisting of both males and females, each weighing about 25 g, were divided into groups of 8 at random.?The tested compounds, Omeprazole and guaiazulene derivatives which were made into suspensions using 5% CMC-Na were administered orally (0.4 mL/20 g) to the dose group, the drug reference group and the GAS-Na group respectively.?While the base control group was treated with only 5% CMC-Na.?Vehicle or test compounds were administered by the oral route once a day for five consecutive days.?After 0.5 h of the last dose, the mice were given orally 0.3 mL of anhydrous ethanol.?Half an hour after anhydrous ethanol administration, the animals were killed.?At last, the stomachs were removed and scored[1].
Synonyms Guaiazulenesulfonate sodium, 磺酸钠
molecular weight 300.35
Molecular formula C15H17NaO3S
CAS 6223-35-4
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility DMSO: 30 mg/mL (99.88 mM)
References 1. Cao T , Li Y , Yang Z , et al. Synthesis and Biological Evaluation of 3, 8-dimethyl-5-isopropylazulene Derivatives as Anti-gastric Ulcer Agent[J]. Chemical Biology & Drug Design, 2016, 88(2):264-271. 2. Nakamichi K , Nakano T , Yasuura H , et al. Stabilization of sodium guaiazulene sulfonate in granules for tableting prepared using a twin-screw extruder[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56(3):0-354.